前列腺癌寡转移治疗的探讨

叶定伟; 万方宁; 戴波

doi:10.13201/j.issn.1001-1420.2022.12.001

前列腺癌寡转移治疗的探讨

- 复旦大学附属肿瘤医院泌尿外科复旦大学上海肿瘤医院肿瘤学系上海市泌尿肿瘤研究所(上海，200032)

详细信息

作者简介:
叶定伟，主任医师、博导，复旦大学附属肿瘤医院副院长、泌尿肿瘤MDT首席专家。上海市泌尿肿瘤研究所所长，复旦大学前列腺肿瘤研究所所长，中国临床肿瘤学会(CSCO)前列腺癌专家委员会主任委员，中国初级卫生保健基金会泌尿外科专委会主任委员，中国抗癌协会泌尿男生殖系肿瘤专委会(CACA-GU)前任主任委员，中华医学会泌尿外科学分会(CUA)肿瘤学组副组长、中国前列腺癌联盟(CPCC)主任委员，中国临床肿瘤学会(CSCO)尿路上皮癌专家委员会副主任委员，中国临床肿瘤学会(CSCO)肾癌专家委员会副主任委员，中国临床肿瘤学会(CSCO)免疫治疗专家委员会副主任委员，中国肿瘤医院泌尿肿瘤协作组(UCOG)主任委员，中国抗癌协会常务理事、中国临床肿瘤学会常务理事，中国抗癌协会泌尿男生殖系肿瘤专委会(CACA-GU)前列腺癌学组组长，NCCN肾癌诊治指南中国版编写组副组长，NCCN前列腺癌、肾癌、膀胱癌亚洲诊治共识专家委员会委员，晚期前列腺癌圣加仑共识专家委员会委员，上海市抗癌协会泌尿肿瘤专委会主任委员，上海市医师协会泌尿外科医师分会副会长，亚太前列腺学会(APPS)候任主席，亚太冷冻外科学会副会长

通讯作者: 叶定伟，E-mail：dwyeli@163.com

中图分类号: R737.25

收稿日期: 2022-09-01

刊出日期: 2022-12-06

Management of oligometastatic prostate cancer

- Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Genitourinary Cancer Institute, Shanghai, 200032, China

More Information

Corresponding author: YE Dingwei, E-mail: dwyeli@163.com

Received Date: 01 September 2022

Publish Date: 06 December 2022

摘要

摘要: 前列腺癌寡转移是一种介于局限期肿瘤和肿瘤广泛转移的中间状态。尽管不同文献对寡转移的定义，提出了不同的看法，但普遍认为盆腔外的转移灶不超过5个。针对寡转移前列腺癌的治疗，近年来越来越多的数据更支持积极治疗。目前文献报道针对原发灶和转移灶的治疗尝试，毒性和副作用可以耐受。寡转移前列腺癌治疗的复杂性也对未来临床研究的设计和实践提出了挑战。
- 前列腺癌 /
- 寡转移 /
- 治疗
Abstract: Oligometastatic prostate cancer(Oligo-mPCa) is an intermediate stage of cancer spread between localized disease and widespread metastases. Although the definition of oligometastatic prostate cancer varies in literatures, a clinical diagnosis made based on up to five extra-pelvic lesions is commonly for use. More and more data supporting the active treatment on oligo-mPCa. Studies suggest that interventions such as radical prostatectomy and local or metastasis-directed radiotherapy is safe and tolerable in oligo-mPCa. However, clinical trials focusing on oligo-mPCa are still challenging due to the complicated settings of oligo-mPCa.
- prostate cancer /
- oligometastases /
- treatment

HTML全文

参考文献(39)

[1]	Hellman S, Weichselbaum RR. Oligometastases[J]. J Clin Oncol, 1995, 13: 8-10. doi: 10.1200/JCO.1995.13.1.8
[2]	Vogelstein B, Kinzler KW. The multistep nature of cancer[J]. Trends Genet, 1993, 9(4): 138-141. doi: 10.1016/0168-9525(93)90209-Z
[3]	Weichselbaum RR, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378-382. doi: 10.1038/nrclinonc.2011.44
[4]	Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol, 2014, 65(6): 1058-1066. doi: 10.1016/j.eururo.2013.11.012
[5]	Fossati N, Trinh QD, Sammon J, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study[J]. Eur Urol, 2015, 67(1): 3-6. doi: 10.1016/j.eururo.2014.08.056
[6]	Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry[J]. Eur Urol, 2014, 66: 602-603. doi: 10.1016/j.eururo.2014.04.009
[7]	Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer[J]. J Clin Oncol, 2016, 34(24): 2835-2842. doi: 10.1200/JCO.2016.67.4788
[8]	Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: A SEER-Medicare Analysis[J]. J Urol, 2015, 194: 378-385. doi: 10.1016/j.juro.2015.02.084
[9]	Boeve LMS, Hulshof M, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD Trial[J]. Eur Urol, 2019, 75: 410-418. doi: 10.1016/j.eururo.2018.09.008
[10]	Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer(STAMPEDE): a randomised controlled phase 3 trial[J]. Lancet, 2018, 392: 2353-2366. doi: 10.1016/S0140-6736(18)32486-3
[11]	Dai B, Zhang S, Wan FN, et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase ii randomized controlled trial[J]. Eur Urol Oncol, 2022, 5(5): 519-525. doi: 10.1016/j.euo.2022.06.001
[12]	Wang B, Liu C, Wei Y, et al. A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early psa progression during castration[J]. Clin Cancer Res, 2020, 26(17): 4551-4558. doi: 10.1158/1078-0432.CCR-20-0587
[13]	Yu EY, Miller K, Nelson J, et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase Ⅲ trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer[J]. J Urol, 2012, 188: 103-109. doi: 10.1016/j.juro.2012.03.008
[14]	Poelaert F, Verbaeys C, Rappe B, et al. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer(LoMP)Trial[J]. Urology, 2017, 106: 146-152. doi: 10.1016/j.urology.2017.02.051
[15]	Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J]. Eur Urol, 2016, 69(5): 788-794. doi: 10.1016/j.eururo.2015.05.023
[16]	Shao YH, Kim S, Moore DF, et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis[J]. Eur Urol, 2014, 65(4): 693-700. doi: 10.1016/j.eururo.2013.05.023
[17]	Löppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis[J]. Eur Urol, 2017, 72(1): 14-19. doi: 10.1016/j.eururo.2016.04.031
[18]	Leyh-Bannurah SR, Gazdovich S, Budäus L, et al. Local therapy improves survival in metastatic prostate cancer[J]. Eur Urol, 2017, 72(1): 118-124. doi: 10.1016/j.eururo.2017.03.020
[19]	Parikh RR, Byun J, Goyal S, et al. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer[J]. Prostate, 2017, 77(6): 559-572. doi: 10.1002/pros.23294
[20]	Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis[J]. Cancer Epidemiol, 2014, 38(4): 435-441. doi: 10.1016/j.canep.2014.04.002
[21]	Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases[J]. Acta Oncol, 2013, 52: 1622-1628. doi: 10.3109/0284186X.2013.764010
[22]	Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A Prospective, Randomized, Multicenter Phase Ⅱ Trial[J]. J Clin Oncol, 2018, 36: 446-453.
[23]	Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases?[J]. Int J Radiat Oncol Biol Phys, 2004, 58: 3-10. doi: 10.1016/S0360-3016(03)01442-1
[24]	Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial[J]. JAMA Oncol, 2020, 6(5): 650-659. doi: 10.1001/jamaoncol.2020.0147
[25]	Zhang H, Orme JJ, Abraha F, et al. Phase Ⅱ evaluation of stereotactic ablative radiotherapy(SABR)and immunity in 11C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2021, 27(23): 6376-6383. doi: 10.1158/1078-0432.CCR-21-2510
[26]	Francolini G, Detti B, Di Cataldo V, et al. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone(ARTO-NCT03449719)[J]. Radiol Med, 2022, 127(8): 912-918. doi: 10.1007/s11547-022-01511-7
[27]	Porres D, Pfister D, Thissen A, et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer[J]. Prostate Cancer Prostatic Dis, 2017, 20(1): 85-92. doi: 10.1038/pcan.2016.54
[28]	Picchio M, Berardi G, Fodor A, et al. (11) C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2014, 41(7): 1270-1279.
[29]	Osmonov DK, Aksenov AV, Trick D, et al. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection[J]. BMC Urol, 2016, 16(1): 56. doi: 10.1186/s12894-016-0173-3
[30]	Battaglia A, De Meerleer G, Tosco L, et al. Novel insights into the management of oligometastatic prostate cancer: a comprehensive review[J]. Eur Urol Oncol, 2019, 2(2): 174-188. doi: 10.1016/j.euo.2018.09.005
[31]	Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2019, 381: 13-24. doi: 10.1056/NEJMoa1903307
[32]	Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase Ⅲ study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer[J]. J Clin Oncol, 2019, 37: 2974-2986. doi: 10.1200/JCO.19.00799
[33]	Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer[J]. N Engl J Med, 2022, 386(12): 1132-1142. doi: 10.1056/NEJMoa2119115
[34]	Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2017, 377: 352-360. doi: 10.1056/NEJMoa1704174
[35]	Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer(LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 686-700. doi: 10.1016/S1470-2045(19)30082-8
[36]	Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase Ⅲ E3805 CHAARTED Trial[J]. J Clin Oncol, 2018, 36(11): 1080-1087. doi: 10.1200/JCO.2017.75.3657
[37]	Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer(PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design[J]. Lancet, 2022, 399(10336): 1695-1707. doi: 10.1016/S0140-6736(22)00367-1
[38]	Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer[J]. N Engl J Med, 2015, 373: 1697-708. doi: 10.1056/NEJMoa1506859
[39]	Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2018, 19: 975-986. doi: 10.1016/S1470-2045(18)30365-6